Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Melanoma Early Detection and Awareness: How Countries Developing Melanoma Awareness Programs Could Benefit From Melanoma-Proficient Countries

Wainstein, Alberto MD, PhD; Algarra, Salvador Martin MD, PhD; Bastholt, Lars DPM, MD; Cinat, Gabriela MD; Demidov, Lev MD, PhD; Grob, Jean Jacques MD; Guo, Jun MD, PhD; Hersey, Peter MSSB, PhD; Espinosa, Enrique MD; Schachter, Jacob MD, PhD; Whitaker, Dagmar MD; Quirt, Ian MD; Hauschild, Axel MD; Rutkowski, Piotr MD, PhD

doi: 10.1097/MJT.0000000000000038
Melanoma Symposium

Risk factors for melanoma are well known and have guided plans for primary and secondary prevention. The presentation of the disease, however, varies widely depending on the geographic area, ethnicity, and socioeconomic status. For this reason, many countries have developed specific strategies to increase public awareness and favor early diagnosis. Awareness campaigns, doctor education, and screening of high-risk subjects have all contributed to improve disease outcome in developed countries. The role of primary care physicians is particularly relevant in this regard. Developing countries are trying to implement similar measures. Future efforts to further improve the efficacy of preventive strategies should focus on populations that usually escape campaigns, such as elderly men and people with low socioeconomic status. Fast-growing tumors also require specific attention.

1Faculdade de Ciências Médicas, Minas Gerais, Brazil;

2Clinica Universitaria de Navarra, Pamplona, Spain;

3Odense University Hospital, Odense, Denmark;

4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina;

5Blokhin Cancer Center, Moscow, Russia;

6Hospital Sainte Marguerite, Marseilles, France;

7Beijing Cancer Hospital, Beijing, China;

8Newcastle University, Newcastle, Australia;

9Hospital La Paz, Madrid, Spain;

10Sheba Medical Center, Tel Hashomer, Israel;

11Melanoma Advisory Board South Africa, Cape Town, South Africa;

12Princess Margaret Hospital, Toronto, Canada;

13University of Kiel, Kiel, Germany;

14M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

Address for correspondence: Rua Amapa 316, Belo Horizonte, Minas Gerais 30240-060, Brazil. E-mail:

Supported by Merck (to L.B.).

G. Cinat received payment for development of educational presentations from BMS, GSK, Roche, and MSD. D. Whitaker and P. Rutkowski received support for travel to meetings from MSD. J. J. Grob is a consultant and board member for Merck, BMS, ESK, and Roche. P. Rutkowski is a board member for MSD and BMS and is a consultant for MSD, Roche, and BMS. The remaining authors have no conflicts of interest to declare.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.